BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 14992916)

  • 1. Gene expression profiles in esophageal adenocarcinoma.
    Dahlberg PS; Ferrin LF; Grindle SM; Nelson CM; Hoang CD; Jacobson B
    Ann Thorac Surg; 2004 Mar; 77(3):1008-15. PubMed ID: 14992916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERBB2 amplifications in esophageal adenocarcinoma.
    Dahlberg PS; Jacobson BA; Dahal G; Fink JM; Kratzke RA; Maddaus MA; Ferrin LJ
    Ann Thorac Surg; 2004 Nov; 78(5):1790-800. PubMed ID: 15511476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systems Biology Analyses Show Hyperactivation of Transforming Growth Factor-β and JNK Signaling Pathways in Esophageal Cancer.
    Blum AE; Venkitachalam S; Ravillah D; Chelluboyina AK; Kieber-Emmons AM; Ravi L; Kresak A; Chandar AK; Markowitz SD; Canto MI; Wang JS; Shaheen NJ; Guo Y; Shyr Y; Willis JE; Chak A; Varadan V; Guda K
    Gastroenterology; 2019 May; 156(6):1761-1774. PubMed ID: 30768984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value and targeted inhibition of survivin expression in esophageal adenocarcinoma and cancer-adjacent squamous epithelium.
    Malhotra U; Zaidi AH; Kosovec JE; Kasi PM; Komatsu Y; Rotoloni CL; Davison JM; R C; Irvin ; Hoppo T; Nason KS; Kelly LA; Gibson MK; Jobe BA
    PLoS One; 2013; 8(11):e78343. PubMed ID: 24223792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isoforms of RNF128 Regulate the Stability of Mutant P53 in Barrett's Esophageal Cells.
    Ray D; Ray P; Ferrer-Torres D; Wang Z; Nancarrow D; Yoon HW; San Martinho M; Hinton T; Owens S; Thomas D; Jiang H; Lawrence TS; Lin J; Lagisetty K; Chang AC; Beer DG
    Gastroenterology; 2020 Feb; 158(3):583-597.e1. PubMed ID: 31715145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
    Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
    Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
    Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-depth characterization of the Wnt-signaling/β-catenin pathway in an in vitro model of Barrett's sequence.
    Götzel K; Chemnitzer O; Maurer L; Dietrich A; Eichfeld U; Lyros O; Moulla Y; Niebisch S; Mehdorn M; Jansen-Winkeln B; Vieth M; Hoffmeister A; Gockel I; Thieme R
    BMC Gastroenterol; 2019 Mar; 19(1):38. PubMed ID: 30841855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic patterns in the progression of esophageal adenocarcinoma.
    Eads CA; Lord RV; Wickramasinghe K; Long TI; Kurumboor SK; Bernstein L; Peters JH; DeMeester SR; DeMeester TR; Skinner KA; Laird PW
    Cancer Res; 2001 Apr; 61(8):3410-8. PubMed ID: 11309301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker identification and trans-regulatory network analyses in esophageal adenocarcinoma and Barrett's esophagus.
    Lv J; Guo L; Wang JH; Yan YZ; Zhang J; Wang YY; Yu Y; Huang YF; Zhao HP
    World J Gastroenterol; 2019 Jan; 25(2):233-244. PubMed ID: 30670912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic changes in microRNA expression profiles reflect progression of Barrett's esophagus to esophageal adenocarcinoma.
    Slaby O; Srovnal J; Radova L; Gregar J; Juracek J; Luzna P; Svoboda M; Hajduch M; Ehrmann J
    Carcinogenesis; 2015 May; 36(5):521-7. PubMed ID: 25784377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
    Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.
    Kauttu T; Mustonen H; Vainionpää S; Krogerus L; Ilonen I; Räsänen J; Salo J; Puolakkainen P
    Clin Transl Oncol; 2017 Jan; 19(1):58-66. PubMed ID: 27026568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subtypes of Barrett's oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis.
    Yu M; Maden SK; Stachler M; Kaz AM; Ayers J; Guo Y; Carter KT; Willbanks A; Heinzerling TJ; O'Leary RM; Xu X; Bass A; Chandar AK; Chak A; Elliott R; Willis JE; Markowitz SD; Grady WM
    Gut; 2019 Mar; 68(3):389-399. PubMed ID: 29884612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
    Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
    Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy.
    Abdel-Latif MM; O'Riordan J; Windle HJ; Carton E; Ravi N; Kelleher D; Reynolds JV
    Ann Surg; 2004 Apr; 239(4):491-500. PubMed ID: 15024310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LKB1 inactivation occurs in a subset of esophageal adenocarcinomas and is sufficient to drive tumor cell proliferation.
    Whitsett TG; Mittal SK; Eschbacher JM; Carson VM; Smith MA; Bremner RM; Inge LJ
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1891-1899. PubMed ID: 29370903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Content Imaging of Barrett's-Associated High-Grade Dysplasia Cells After siRNA Library Screening Reveals Acid-Responsive Regulators of Cellular Transitions.
    Phipps SM; Garry CE; Kamal S; Johnson JD; Gilmer J; Long A; Kelleher D; Duggan SP
    Cell Mol Gastroenterol Hepatol; 2020; 10(3):601-622. PubMed ID: 32416156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic similarity between gastroesophageal junction and esophageal Barrett's adenocarcinomas.
    Ferrer-Torres D; Nancarrow DJ; Kuick R; Thomas DG; Nadal E; Lin J; Chang AC; Reddy RM; Orringer MB; Taylor JM; Wang TD; Beer DG
    Oncotarget; 2016 Aug; 7(34):54867-54882. PubMed ID: 27363029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.